The phenotype of mixed connective tissue disease patients having associated interstitial lung disease.

Connective tissue disease Interstitial lung disease Lung fibrosis Mixed connective tissue disease

Journal

Seminars in arthritis and rheumatism
ISSN: 1532-866X
Titre abrégé: Semin Arthritis Rheum
Pays: United States
ID NLM: 1306053

Informations de publication

Date de publication:
Dec 2023
Historique:
received: 16 04 2023
revised: 17 07 2023
accepted: 15 08 2023
pubmed: 12 9 2023
medline: 12 9 2023
entrez: 11 9 2023
Statut: ppublish

Résumé

We aimed to compare two matched populations of patients with MTCD with and without associated ILD and to identify predictive factors for ILD progression and severity. This international multicenter retrospective study (14 tertiary hospitals), included MCTD patients who fulfilled at least one historical MCTD classification criteria. ILD was defined by the presence of typical chest high-resolution computed tomography (HRCT) abnormalities. Factors associated with ILD were assessed at baseline. Long-term progressive ILD was assessed in MCTD-ILD patients with multiple forced vital capacity (FVC) measurements. 300 patients with MCTD were included. Mean age at diagnosis was 39.7 ± 15.4 years and 191 (63.7%) were women. Mean follow-up was 7.8 ± 5.5 years. At baseline, we identified several factors associated with ILD presence: older age (p = 0.01), skin thickening (p = 0.03), upper gastro-intestinal (GI) symptoms (p<0.001), FVC <80% (p<0.0001), diffusing capacity for carbon monoxide <80% (p<0.0001), anti-topoisomerase antibodies (p = 0.01), SSA/Ro antibodies (p = 0.02), cryoglobulinemia (p = 0.04) and elevated C-reactive protein (p<0.001). Patients with MTCD-ILD were more likely to be treated with synthetic immunosuppressant agents (p<0.001) in particular mycophenolate mofetil (p = 0.03). Digital ulcers (DU) were identified as a risk factor for FVC decline >10%. During follow-up mortality was higher in the MTCD-ILD group (p<0.001). In this large international cohort of patients with MTCD, we identified different factors associated with ILD. Our findings also provide evidence that MCTD-ILD patients have increased mortality and that DU are associated with progressive lung disease.

Identifiants

pubmed: 37696231
pii: S0049-0172(23)00100-2
doi: 10.1016/j.semarthrit.2023.152258
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

152258

Informations de copyright

Copyright © 2023. Published by Elsevier Inc.

Déclaration de conflit d'intérêts

Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Auteurs

Gonçalo Boleto (G)

Department of Rheumatology, Université Paris Cité, Cochin Hospital, Paris, France; Instituto Português de Reumatologia, Lisboa, Portugal.

Silje Reiseter (S)

Department of Rheumatology, Martina Hansen Hospital, Sandvika, Norway.

Anna-Maria Hoffmann-Vold (AM)

Department of Rheumatology, Oslo University Hospital, Oslo, Norway.

Adrien Mirouse (A)

Department of Internal Medicine and Clinical Immunology, Groupe Hospitalier Pitié-Salpêtrière, AP-HP, Paris F-75013, France.

Patrice Cacoub (P)

Department of Internal Medicine and Clinical Immunology, Groupe Hospitalier Pitié-Salpêtrière, AP-HP, Paris F-75013, France.

Marco Matucci-Cerinic (M)

Unit of Immunology, Rheumatology, Allergy and Rare Diseases (UNIRAR), Irccs San Raffaele Hospital, Milan, Italy; Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy.

Manuel Silvério-António (M)

Serviço de Reumatologia e Doenças Ósseas Metabólicas, Centro Hospitalar Universitário Lisboa Norte and Instituto de Medicina Molecular, Faculdade de Medicina, Universidade de Lisboa, Centro Académico de Medicina de Lisboa (CAML), Lisbon, Portugal.

Joao Eurico Fonseca (JE)

Serviço de Reumatologia e Doenças Ósseas Metabólicas, Centro Hospitalar Universitário Lisboa Norte and Instituto de Medicina Molecular, Faculdade de Medicina, Universidade de Lisboa, Centro Académico de Medicina de Lisboa (CAML), Lisbon, Portugal.

Ana Catarina Duarte (AC)

Serviço de Reumatologia, Hospital Garcia de Orta, Almada, Portugal.

Jorge Pestana Lopes (J)

Serviço de Reumatologia, Hospital Garcia de Orta, Almada, Portugal.

Valeria Riccieri (V)

Department of Clinical, Internal, Anaesthesiologic, Cardiologic Sciences, University of Rome Sapienza, Rome, Italy.

Alain Lescoat (A)

Department of Internal Medicine and Clinical Immunology, Rennes University Hospital, Rennes, France.

Erwan Le Tallec (E)

Department of Internal Medicine and Clinical Immunology, Rennes University Hospital, Rennes, France.

Ivan Castellví Barranco (I)

Department of Rheumatology and Systemic Autoimmune Diseases, Hospital Universitari de la Santa Creu i Sant Pau, Barcelona, Spain.

Jose Luis Tandaipan (JL)

Department of Rheumatology and Systemic Autoimmune Diseases, Hospital Universitari de la Santa Creu i Sant Pau, Barcelona, Spain.

Paolo Airó (P)

Rheumatology and Clinical Immunology Unit, Spedali Civili, Brescia, Italy.

Masataka Kuwana (M)

Department of Allergy and Rheumatology, Nippon Medical School Graduate School of Medicine, Tokyo, Japan.

Hoda Kavosi (H)

Rheumatology Research Center, Shariati Hospital, Tehran University of Medical Sciences, Kargar Avenue, 14117-13137, Tehran, Iran.

Jérôme Avouac (J)

Department of Rheumatology, Université Paris Cité, Cochin Hospital, Paris, France; INSERM U1016, Institut Cochin, CNRS UMR8104, Paris, France.

Yannick Allanore (Y)

Department of Rheumatology, Université Paris Cité, Cochin Hospital, Paris, France; INSERM U1016, Institut Cochin, CNRS UMR8104, Paris, France. Electronic address: yannick.allanore@aphp.fr.

Classifications MeSH